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The present status of cancer chemotherapy can be reviewed in light of selected basic
principles with an acknowledgement of the role
of established chemotherapeutic agents. Four
chemotherapeutic agents recently approved for
clinical use and their impact when used in combination regimens should be examined. Several
important concepts influencing chemotherapy
in the 1980s include the use of chemotherapy
in the adjuvant setting, the use of hormonal receptor data in planning therapy, and the use of
in vitro tests on tumor specimens to predict tumor sensitivity to cancer chemotherapy drugs
(prior to administration of these potentially toxic
drugs to a particular patient). Lastly the reader is
cautioned about the potential of long-term complications with certain chemotherapy agents ,
especially in those patients who have had complete or extended partial remissions.

Review
The modern era of cancer chemotherapy
began approximately 40 years ago when nitrogen mustard , a derivative of the mustard gases
used in the World Wars, was demonstrated to
cause regression of lymphomatous tumors initially in studies involving mice and later man.
Since that time a variety of chemicals and natural products have been synthesized (or isolated)
and subjected to various screening programs in
an attempt to identify potential clinically-effective drugs. Today there are approximately 30
drugs that have been approved and deemed
valuable in the treatment of various human cancers. 1 These agents can be categorized into six
major classes (Table 1 ).
The development of these diverse agents
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which effect various critical biochemical steps
or processes has occurred during a period in
which there have been rapid and significant
gains in our understanding of the molecular biology of the cell. Concomitantly, there has been
an increased understanding of tumor cell biology which has markedly influenced the way
cancer chemotherapy drugs are used today .
Cell kinetic studies in animal models have demonstrated that a single malignant cell can multiply within a host animal to eventually kill the
host. Thus curative therapeutic approaches
must aim to eradicate every malignant cell .
Studies with anticancer agents in animal models
have shown that chemotherapy kills cells in a
first-order kinetic manner, ie , with each treatment a constant percentage (rather than a constant number) of cells is killed . These generally
accepted "principles" have provided support
for the aggressiveness now used in many of the
multiagent chemotherapy regimens and have
formed the basis for adjuvant and maintenance
chemotherapy .2
Multiagent , or combination chemotherapy, the major approach used in advanced cancer today, has been influenced by a better comprehension of the cell cycle . Thus it is
recognized that certain drugs act on cells only
in a specific phase of the cell cycle (the life
cycle through which a cell passes from its origin
when formed from the mother cell to the point at
which it in turn divides into daughter cells) while
other drugs are non-cycle specific, being able
to affect cells regardless of where they are in
the cell cycle, including cells not actively replicating . The recognition of this concept has
been utilized in designing effective combination
regimens which aim at affecting cells in different
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phases of the cell cycle to obtain the maximum
therapeutic effect.
The success of chemotherapy in the management of human cancer can be seen in Tables 2 and 3 .2 Table 2 demonstrates that in at
least seven tumor types, chemotherapy now offers either cure or at the very least a significant
prolongation of life. While actual cure has not
been achievable for the five tumors listed in
Table 3 , there nevertheless has been a demonstrated increased survival and palliation . For the
remaining tumor types not listed, including the
relatively frequent cancers such as carcinoma
of the lung and large bowel , cure and palliation
are less likely at present. With the development
of new agents, it is hoped that more effective
combination regimens will be created to improve survival in these currently less responsive
tumors as well.

TABLE 1
Classification of Cancer Chemotherapy Agents
Alkylating Agents
Mechlorethamine (Mustargen)
Cyclophosphamide (Cytoxan)
Chlorambucil (Leukeran)
Melphalan (Alkeran)
Triethylenethiophosphoramide (thiotepa)
Nitrosoureas
(BCNU or Carmustine)
(CCNU or Lomustine)
(5-(3 ,3-Dimethyl-1-triazene)-imidazole-4carboxamide)
(Dacarbazine or DTIC)
Antimetabolites
Methotrexate
5-Fluorouracil (Fluorouracil, Adrucil)
Cytosine arabinoside (ara-C or cytosar)
6-mercaptopurine (Purinethol)
6-thioguanine (thioguanine)
Antibiotic
Dactiomycin (actinomycin D. (Cosmergen))
Mithromycin (Mithracin)
Doxorubicin (Adriamycin)
Daunorubicin (Daunomycin)
Mitomycin C (Mutamycin)
Bleomycin (Blenoxane)
Natural Products
Vinblastine (Velban)
Vincristine (Oncovin)
L-Asparaginase (E.lspar)
Miscellaneous Agents
o,p '-DDD (Mitotane (Lysodren))
Hydroxyurea (Hydrea)
Procarbazine (Matulane)
Cis-platinum diamine dichloride (Cisplatin , Platinol)
Hormones
Estrogens
Androgens
Progestational Steroids
Adrenal Steroids
Antiestrogen tamoxifen citrate (Nolvadex)

Update
Over the past several years there have
been four new agents introduced clinically that
are now not only approved for non-investigational use but. also occupy important roles in
cancer chemotherapy already. The increasing
use of all four drugs necessitates a basic understanding of them by every physician participating in the care of a particular cancer patient.
Doxorubicin (Adriamycln)
Perhaps the most important new agent is
Adriamycin . This drug and the closely related
drug Daunorubicin (Daunomycin) are anthracyclene derivatives obtained as fermentation
products from Streptomyces (Fig 1). These
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TABLE 2
Cure or Increased Survival
Type of Cancer
Gestational trophoblastic tumors

Burkitt 's tumor
Testicular tumors (nonseminoma)

Wilms ' tumor
Neuroblastoma
Acute lymphoblastic leukemia

Hodgkin's disease , stage 1118 and IV

Chemotherapy
Methotrexate, dactinomycin,
vinblastine
Cyclophosphamide (many others)
Dactinomycin ,
Methotrexate chlorambucil,
Bleomycin , Cis-platinum diamine
dichloride
Dactinomycin plus vincristine with
surgery and radiotherapy
Cyclophosphamide with surgery
and /or radiotherapy
Daunorubicin, prednisone , vincristine,
6-mercaptopurine, Methotrexate,
BCNU
MOPP, ABVD

Results

70% cured
50% cured
70-80% respond; 2-3% cured

30-40% cured
5% cured
90% remission ; 70% survive beyond
5 years
70% respond; 40% survive beyond
5 years

(Note: Adapted from I H Krakoff , Cancer Chemotherapeutic Agents, Ca-A Cancer Journal of Clinicians, 27, 1977 , 132.)

(By Permission)

drugs are classified as antibiotic cancer chemotherapy agents.
The mechanism of action of both drugs is
believed to be via inhibition of DNA synthesis.
These agents are known to interact with DNA,
eventually intercalating into the nucleic acid helix leading to uncoiling of the DNA and inhibiting
both RNA and DNA synthesis. Both agents are
maximally effective during the S phase of the
cell cycle , but inhibition can occur at all stages
of the cell cycle, particularly at higher concentrations .3
The pharmacology of these drugs is still
somewhat incomplete. At present they are used
only intravenously. The major site of metabolism
is in the liver by both soluble and microsomal
enzymes. Less than 1 0% of the drug is excreted in the urine. Because of the importance
of liver metabolism, the dose of Adriamycin is
reduced in the presence of hepatic dysfunction .
No drug adjustments are made for renal dysfunction . The total dose should not exceed
550-600 mg/M 2 . 2 · 3
Both drugs have similar side effects and
toxicities including: 1) gastrointestinal (nausea ,
vomiting, diarrhea, and stomatitis); 2) hematologic (leukopenia with a nadir at 1 0-1 5 days,
and thrombocytopenia); 3) dermatologic (alopecia, local phlebitis and necrosis if extravasated); 4) cardiac (by far the most serious toxicity with these drugs is manifested as
congestive heart failure due to a diffuse cardiomyopathy).
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The major indications for Daunorubicin
(Daunomycin) have been in acute granulocytic,
and in lymphocytic, leukemia . In contrast,
Doxorubicin (Adriamycin) has been active not
only in leukemia but also in bladder cancer,
breast cancer , bronchiogenic cancer, Hodgkin
and non-Hodgkin lymphoma , thyroid cancer
and sarcomas in general.
Bleomycin (Blenoxane)

Bleomycin, also of the antibiotic class of
chemotherapy agents isolated from Streptomyces, is actually a mixture of several similar
polypeptides, each having a molecular weight
of approximately 1500. The A2 peptide is the
major compound present in the commercial
preparation and is believed to be the active
component (Fig 2).
The mechanism of action of Bleomycin
appears to be by scission of double-stranded
DNA, resulting in fragmentation of DNA, in turn
causing inhibition of DNA synthesis . This drug
appears to block cells at the G2 /M interphase
of the cell cycle.
The pharmacology of this drug in vivo has
been limited by the fact that the drug is a mixture of several compounds . Following administration, it disappears rapidly from the plasma
with an estimated half life of 1 5-60 minutes.
Since the dq..1g is known to be excreted primarily
via the kidneys, the dose should be reduced in
the presence of renal dysfunction . Bleomycin is
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degraded mainly by the action of animonopeptidase which is present in tumor cells,
liver and kidney. It is absent from the skin and
lungs, two tissues which are particularly susceptible to damage from this drug. Bleomycin is administered either intravenously, intramuscularly, or subcutaneously. 2 •3
As noted above, Bleomycin toxicity includes skin toxicity (such as hyperpigmentation,
thickening, ulceration, rash, alopecia, or nail
changes) and pulmonary toxicity. This last severe toxic finding may be present as pneumonitis with dyspnea, rAles and infiltrate progress-

Type of Cancer
Prostate carcinoma
Breast carcinoma

Chronic lymphocytic leukemia
Lymphosarcoma
Acute myeloblastic leukemia

ing to fibrosis. The occurrence of toxicity need
not be related to the cumulative dose although it
is more frequent with a total dose greater than
250 units/M 2 or a single dose greater than 25
units/M 2 . The risk is increased particularly in individuals more than 50 years old who may have
prior lung disease or may have previously been
treated with radiation therapy. Pulmonary function tests have not been of value in predicting
pulmonary toxicity. A cumulative dose of 400
units is the accepted maximum dose. Since the
drug is a polypeptide, a potential side effect
with this agent is anaphylaxis. Fever and chills

TABLE 3
Palliation and Prolongation of Life
Results
Chemotherapy
70% respond with some prolongation
Estrogens, castration, cyclophosof life
phamide
60-80% respond with probable
Androgens, estrogens, alkylating
prolongation of life
agents, 5-fluorouracil, vincristine,
prednisone, Methotrexate,
Adriamycin
50% respond with probable prolongaPrednisone, alkylating agents
tion ofme
50% respond with probable
Prednisone, alkylating agents
prolongation of lifa
65% remission with prolongation
Cytosine arabinoside and
of life
thioguanine

(Note: Adapted from IH Krakoff, Cancer Chemotherapeutic Agents, Ca-A Cancer Journal of Clinicians, 27, 1977, 132.)

(By Permission)
DIASIO: RECENT ADVANCES IN CANCER CHEMOTHERAPY /

81

cis-Diamminedichloroplatinum
Fig. 3.

occur in 20-30% of patients . The possibility of
hypersensitivity is particularly a problem in lymphoma. Nausea and vomiting may also occur
with administration of Bleomycin . One toxic
manifestation notably absent with this chemotherapeutic agent is the lack of hematologic toxicity making this drug especially appealing for
combination chemotherapy.
The major indications for Bleomycin have
been in lymphomas (Hodgkin and non-Hodgkin}, testicular tumors, and squamous cell carcinoma of the head and neck. Other indications
are less clear at this time .

Cis-Diamminedichloroplatlnum (Cis-platinum, Platinol)
This agent is a heavy metal coordination
complex of platinum containing two ammonia
groups and two chlorines in the Cis conformation (Fig 3) . It is listed as a random synthetic type of chemotherapeutic drug . The
mechanism of action appears to be through inhibition of DNA synthesis thought to result from
both interstrand and intrastrand crosslinks in
DNA. It appears to be cycle non-specific.
Cis-platinum is administered in an intravenous solution usually in an infusion from 1 5
minutes to eight hours. Following administration, plasma levels of the drug show a biphasic
pattern of decay with an initial half life of 2 5 to
50 minutes and a terminal half life of 58 to 72
hours. Studies of distribution have demonstrated the greatest uptake in the excretory organs, ovary, and uterus. More than 90% of the
platinum following administration is protein
bound. Cis-platinum is excreted mainly via the
urine. This drug should be used with caution or
even withheld if renal dysfunction occurs with a
82 /

creatinine clearance of <60 ml/min . An attempt has been made to minimize renal toxicity
secondary to Cis-platinum administration by
hydrating the patient prior to drug receipt, giving
diuretics and infusing chemotherapy slowly.
The renal toxicity appears to be dose related. Close follow-up of BUN, creatinine, and
uric acid , and particularly creatinine clearance
is advisable. Other side effects include ototoxicity, relatively frequent nausea and vomiting,
leukopenia, thrombocytopenia, and anemia .
Anaphylactic reactions have been described in
no more than 1% of the patients given this
drug . Peripheral neuropathies and loss of taste
are less common side effects. 4 This drug appears to be active in testicular tumors, ovarian
cancer, bladder cancer, and head and neck
cancer.

Tamoxifen Citrate (Nolvadex)
Tamoxifen is a synthetic non-steroidal triphenylethylene derivative that has been demonstrated to have potent anti-estrogen activity in
several mammalian species . It is classified as a
hormonal type of chemotherapy agent (Fig 4 ).
The mechanism of action appears to involve inhibition of estrogen binding to cyctoplasmic estrogen receptors present in sensitive cells such
as breast cancer. It is believed that following
binding to the receptor, estradiol-estrogen receptor formation is blocked. Since this receptor
is necessary for activation of certain nucleic
acid processes, the hormonal response of these
cells is blocked .
This drug is given orally in 1 Omg tablets.
Following oral administration , peak levels occur
within four to seven hours. The initial half life is
estimated to be from seven to 1 4 hours. Pro-
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longed blood levels may therefore occur. This is
thought to be due to concentration and excretion into the bile tract with reabsorption through
the enterohepatic circulation.
Toxicity due to antiestrogenic actions include hot flashes, vaginal bleeding, menstrual
irregularities, and pruritis vulvae. Non-specific
gastrointestinal side effects have been described such as nausea, vomiting and distaste
for food . Other toxic manifestations may include
fluid retention, hypocalcemia, ahd dizziness.5
The major indication at present is in palliative treatment of advanced metastatic breast
carcinoma. The use of this drug in estrogen-receptor positive premenopausal women with
breast cancer is currently being evaluated by
the National Surgical Adjuvant Breast Project.
New Combinations

The addition of these new agents has
made possible new combinations taking into
account not only the principle of cell cycle and
cell kinetics suggested earlier, but also permitting modification of toxicity since many of these
new agents have toxicity different from many of
the standard agents in chemotherapy. For example, Bleomycin and Tamoxifen have essentially no hematologic toxicity and are attractive
to use in combination with agents that might
cause marked hematologic toxicity. Two particularly interesting new combinations include the
ABVD regimen (Adriamycin, Bleomycin, Vinblastine and 5-(3, 3-Dimethyl-1-triazene)~imidazole-4-carboxamide) used in Hodgkin disease
and the Cis-platinum-Bleomycin-Vinblastine
combination used in testicular cancer.6
The ABVD combination has been shown
to be approximately equally active to the MOPP
combination (Mechlorethamine + Oncovin
+prednisone+procarbazine) used in the treatment of advanced Hodgkin disease. More importantly, there appears to be little cross resistance of the ABVD regimen with the MOPP
combination making possible a suitable alternative treatment for MOPP failures. The combined
use of Bleomycin and Adriamycin has also been
shown to be active in some recent combinations
used in non-Hodgkin lymphomas as well. 7
In testicular cancers the contribution of
these new agents (Bleomycin and particularly
Cis-platinum) is even more impressive. While
several active agents have been available for

many years including Methotrexate, Actinomycin D, and Mithramycin , the percentage of
complete remissions was consistently 30% or
less with no prolonged survivals. The combination of Cis-platinum-Vinblastine-Bleomycin has
resulted in complete remission rates of 70% or
greater with an increased percentage of prolonged survivors. 8 The evolution of chemotherapy in the treatment of testicular cancer with
first the addition of Bleomycin and later the addition of platinum illustrates the point made earlier that as new agents are introduced in combination with other effective agents, there is hope
that still more effective combinations will be
found in the treatment of other cancers as well.
Adjuvant Chemotherapy
Adjuvant chemotherapy is usually defined
as the use of chemotherapy together with surgery and/or radiotherapy. As suggested earlier,
cell kinetics provide a rationale for the use of
adjuvant chemotherapy. Following removal of a
tumor mass and a curative resection , the cell
number should be reduced dramatically. When
the cell number is relatively low, tumor cells are
more likely to be actively growing and dividing .
Since most chemotherapeutic drugs will kill
cancer cells actively "in phase" in the cell
cycle, it should follow that the smaller the tumor
mass, the larger the growth fraction and the
more likely the cells are to respond to cytotoxic
drugs. The fact that only one cell is needed to
theoretically kill the host, and the fact that
chemotherapeutic drugs kill in a first-order kinetic manner, further supports the rationale for
chemotherapy in the adjuvant setting . A number
of experimental studies using mouse and rat tumor models have substantiated the value of adjuvant chemotherapy in prolonging survival. 9
Clinical trials have now demonstrated a
definite role for adjuvant chemotherapy in at
least delaying the occurrence of metastases in
premenopausal patients with breast cancer. It is
still somewhat early to evaluate the overall effect on survival, although it does not appear to
be as promising as originally hoped. Two regimens have been used in extensive adjuvant
studies in breast cancer in this country and
abroad. The American study has utilized the alkylating agent L-phenylalanine mustard, while
the European study from Italy has utilized the
combination of Cyclophosphamide, Methotrexate and 5-fluorouracil . Both studies have dem-
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onstrated a definite role in premenopausal cancer, although the role in _postmenopausal
cancer is somewhat less clear. 1 0
On osteogenic sarcoma there has been a
dampening of the original enthusiasm for adjuvant chemotherapy. The initial regimens used
during the past five years have included the use
of Adriamycin with and without other agents
and the use of high-dose Methotrexate. In these
studies there has been the suggestion that
again metastases may be delayed; but in this
case it appears much less likely that any overall
improvement of survival has resulted. 9
For other tumor types the role of adjuvant
chemotherapy . at present remains much less
clear. There is, however, the hope that with
newer agents resulting in more effective combinations, there will be increased effectiveness of
these drugs used early in the course of the disease with the anticipation that not only the onset
of metastatic lesions will be delayed but also
that survival time will be prolonged .
Receptor Status
Over the past several years there has
been widespread acceptance by the medical
and surgical community of the importance of
obtaining breast tumor specimens at the time of
surgery for assessmer,t of estrogen as well as
possibly other hormonal receptors. 11 The estrogen receptor assay has been shown to have a
positive correlation greater than 65% with response to hormonal therapy in several large
studies recently completed. Fwrthermore, patients with estrogen~receptor negative tumors
appear not to respond to hormonal therapy . The
most important impact of this receptor data is
that approximately a third of all breast patients
with metastasis are estimated not to respond to
hormonal therapy. With the use of the hormonal
· receptor assays, patients who are estrogen-receptor negative may be spared ineffective therapy and may be begwn on more effective cytotoxic chemotherapy at an earlier point.
Less clear is the importance of estrogenreceptor negative status in premenopausal
patients. Recently it has been suggested in a
retrospective study conducted at the National
Cancer Institute that estrogen-receptor negative
patients may actually respond better to chemotherapy than estrogen-receptor positive
patients. This study, however, has been contradicted by yet another retrospective study. At
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th~ present time prospective studies are needed
to clarify this hypothesis, and no recommendations can be made. 12
Prediction of Drug Response
For many years there has been the hope
that one could test tumor cells, much as one
tests bacteria cultured from an infected patient,
thereby making a more rational choice of the
agent or agents to be used. To some extent this
approach has already been adopted in breast
cancer where the presence or absence of estro. gen receptors in the tumor specimen from a
particular patient may determine whether hormonal therapy will be used. Recently a new
method was demonstrated which permits tumor
cells, obtained from specimens at the time of
surgery, to be cultured so that drugs may be
tested for possible effect. While only a limited
number of cases have been studied at the present time , data in multiple myeloma and ovarian
cancers suggest that the possibility exists that
indeed a predictive test may be possible , 13
thereby at the very least preventing the use of
ineffective cytotoxic drugs and possibly determining effective drugs that may be used in the
treatment of the individual patient. Again research will be conducted in the 1980s which
will further clarify the usefulness of this new
method. 14
Long-Term Effects of Chemotherapy
While the immediate and idiosyncratic effects of the various chemotherapeutic agents
have been well known, it is now clear that some
of these drugs, particularly the alkylating agents
and those drugs that intercalate into DNA, may
result in the development of secondary neoplasms. These usually occur four to five years
after the initial chemotherapy has been completed . 15 The implication is that the very patients
- who have been ''cured'' by chemotherapy have
then gone on to develop neoplasms secondary
to the initial chemotherapy. This has now been
seen in an increasing number of chemoresponsive tumors; eg with the use of alkylating
agents in multiple myeloma or with alkylating
agents with or without radiotherapy in Hodgkin
disease.
The effects of radiotherapy have long
been known to be associated with secondary
neoplasms so that patients receiving radiotherapy and chemotherapy with agents which
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interfere with the DNA structure may be especially at risk. With the development of more effective combinations, it is hoped that some of
the agents responsible for these catastrophic
toxicities may be removed and replaced by
·' non-carcinogenic'' drugs.
Lastly, there will be a need to review the
use of certain potentially ''carcinogenic'' agents
in adjuvant regimens, especially in those patients who may indeed have been cured by surgery. With more experience it is hoped that the
more toxic agents may be removed from these
combinations as well.
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